Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSION: Olaparib Maintenance in Chemotherapy-Sensitive Metastatic Pancreatic Adenocarcinoma
2025-522530-31-01Phase 2Authorised
- Sponsor
- Università degli Studi di Verona
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib in pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by Università degli Studi di Verona. Primary endpoint: Overall Survival rate at 12 months after starting olaparib maintenance (OS@12-mo). Planned start Feb 2026; status: authorised.
02
Drugs
olaparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-522530-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522530-31-01.